JPH01100126A - Aids-preventing and treating composition - Google Patents
Aids-preventing and treating compositionInfo
- Publication number
- JPH01100126A JPH01100126A JP25726887A JP25726887A JPH01100126A JP H01100126 A JPH01100126 A JP H01100126A JP 25726887 A JP25726887 A JP 25726887A JP 25726887 A JP25726887 A JP 25726887A JP H01100126 A JPH01100126 A JP H01100126A
- Authority
- JP
- Japan
- Prior art keywords
- soybean
- saponin
- cells
- formula
- aids
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 12
- 229930182490 saponin Natural products 0.000 claims abstract description 42
- 150000007949 saponins Chemical class 0.000 claims abstract description 42
- 239000001397 quillaja saponaria molina bark Substances 0.000 claims abstract description 34
- 244000068988 Glycine max Species 0.000 claims abstract description 30
- 235000010469 Glycine max Nutrition 0.000 claims abstract description 25
- 208000030507 AIDS Diseases 0.000 claims abstract description 20
- 239000004480 active ingredient Substances 0.000 claims abstract description 4
- 125000000896 monocarboxylic acid group Chemical group 0.000 claims abstract 3
- 239000000126 substance Substances 0.000 claims description 12
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 abstract description 15
- 238000000605 extraction Methods 0.000 abstract description 8
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 abstract description 6
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 abstract description 6
- 241000221198 Basidiomycota Species 0.000 abstract description 3
- 238000000197 pyrolysis Methods 0.000 abstract description 3
- 239000003960 organic solvent Substances 0.000 abstract description 2
- CBOIHMRHGLHBPB-UHFFFAOYSA-N hydroxymethyl Chemical compound O[CH2] CBOIHMRHGLHBPB-UHFFFAOYSA-N 0.000 abstract 2
- 241000196324 Embryophyta Species 0.000 abstract 1
- 230000003450 growing effect Effects 0.000 abstract 1
- 239000001963 growth medium Substances 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 39
- 235000017709 saponins Nutrition 0.000 description 37
- 238000012360 testing method Methods 0.000 description 25
- 230000000694 effects Effects 0.000 description 20
- 241000700605 Viruses Species 0.000 description 15
- 102000036639 antigens Human genes 0.000 description 14
- 108091007433 antigens Proteins 0.000 description 14
- 208000015181 infectious disease Diseases 0.000 description 13
- 239000000427 antigen Substances 0.000 description 12
- 238000000034 method Methods 0.000 description 12
- 229940079593 drug Drugs 0.000 description 11
- 239000003814 drug Substances 0.000 description 11
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 9
- 230000003013 cytotoxicity Effects 0.000 description 9
- 231100000135 cytotoxicity Toxicity 0.000 description 9
- 230000001629 suppression Effects 0.000 description 9
- HBOMLICNUCNMMY-XLPZGREQSA-N zidovudine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](N=[N+]=[N-])C1 HBOMLICNUCNMMY-XLPZGREQSA-N 0.000 description 7
- 229960002555 zidovudine Drugs 0.000 description 7
- 235000000346 sugar Nutrition 0.000 description 6
- 230000003612 virological effect Effects 0.000 description 6
- 208000031886 HIV Infections Diseases 0.000 description 4
- 208000037357 HIV infectious disease Diseases 0.000 description 4
- -1 glycoside compounds Chemical class 0.000 description 4
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 4
- 125000003523 triterpene group Chemical group 0.000 description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- TWCMVXMQHSVIOJ-UHFFFAOYSA-N Aglycone of yadanzioside D Natural products COC(=O)C12OCC34C(CC5C(=CC(O)C(O)C5(C)C3C(O)C1O)C)OC(=O)C(OC(=O)C)C24 TWCMVXMQHSVIOJ-UHFFFAOYSA-N 0.000 description 3
- PLMKQQMDOMTZGG-UHFFFAOYSA-N Astrantiagenin E-methylester Natural products CC12CCC(O)C(C)(CO)C1CCC1(C)C2CC=C2C3CC(C)(C)CCC3(C(=O)OC)CCC21C PLMKQQMDOMTZGG-UHFFFAOYSA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 230000036436 anti-hiv Effects 0.000 description 3
- 229930182470 glycoside Natural products 0.000 description 3
- PFOARMALXZGCHY-UHFFFAOYSA-N homoegonol Natural products C1=C(OC)C(OC)=CC=C1C1=CC2=CC(CCCO)=CC(OC)=C2O1 PFOARMALXZGCHY-UHFFFAOYSA-N 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- SMRPGWBDLOQHOS-UHFFFAOYSA-N 5-[4,5-dihydroxy-6-(hydroxymethyl)-3-(3,4,5-trihydroxy-6-methyloxan-2-yl)oxyoxan-2-yl]oxy-3,4-dihydroxy-6-[[9-hydroxy-4-(hydroxymethyl)-4,6a,6b,8a,11,11,14b-heptamethyl-14-oxo-2,3,4a,5,6,7,8,9,10,12,12a,14a-dodecahydro-1H-picen-3-yl]oxy]oxane-2-carboxylic acid Chemical compound OC1C(O)C(O)C(C)OC1OC1C(OC2C(OC(C(O)C2O)C(O)=O)OC2C(C3C(C4C(C5(CCC6(C)C(O)CC(C)(C)CC6C5=CC4=O)C)(C)CC3)(C)CC2)(C)CO)OC(CO)C(O)C1O SMRPGWBDLOQHOS-UHFFFAOYSA-N 0.000 description 2
- 208000009746 Adult T-Cell Leukemia-Lymphoma Diseases 0.000 description 2
- 208000016683 Adult T-cell leukemia/lymphoma Diseases 0.000 description 2
- 208000035473 Communicable disease Diseases 0.000 description 2
- 239000004378 Glycyrrhizin Substances 0.000 description 2
- 208000029462 Immunodeficiency disease Diseases 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- BMWPBKOFJSHJAW-UHFFFAOYSA-N Saponin B Natural products CC1(C)CCC2(CCC3(C)C(=CCC4C5(C)CCC(OC6OC(CO)C(O)C(OC7OC(CO)C(O)C(O)C7O)C6=O)C(C)(C)C5CCC34C)C2C1)C(=O)O BMWPBKOFJSHJAW-UHFFFAOYSA-N 0.000 description 2
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 201000006966 adult T-cell leukemia Diseases 0.000 description 2
- 239000000287 crude extract Substances 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 description 2
- 229960004949 glycyrrhizic acid Drugs 0.000 description 2
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 description 2
- 235000019410 glycyrrhizin Nutrition 0.000 description 2
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 230000003449 preventive effect Effects 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- PPRSVUXPYPBULA-UHFFFAOYSA-N saponin A Natural products CC1(C)CCC2(CCC3(C)C(=CCC4C5(C)CCC(OC6OC(CO)C(O)C(O)C6=O)C(C)(C)C5CCC34C)C2C1)C(=O)O PPRSVUXPYPBULA-UHFFFAOYSA-N 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- UZFMOKQJFYMBGY-UHFFFAOYSA-N 4-hydroxy-TEMPO Chemical compound CC1(C)CC(O)CC(C)(C)N1[O] UZFMOKQJFYMBGY-UHFFFAOYSA-N 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- 230000006820 DNA synthesis Effects 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 240000004670 Glycyrrhiza echinata Species 0.000 description 1
- 235000001453 Glycyrrhiza echinata Nutrition 0.000 description 1
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 description 1
- 235000017382 Glycyrrhiza lepidota Nutrition 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 241000714260 Human T-lymphotropic virus 1 Species 0.000 description 1
- 206010061598 Immunodeficiency Diseases 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 206010060860 Neurological symptom Diseases 0.000 description 1
- 235000002789 Panax ginseng Nutrition 0.000 description 1
- 240000004371 Panax ginseng Species 0.000 description 1
- KYWSCMDFVARMPN-LCSVLAELSA-N Saikosaponin D Chemical compound O([C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@]([C@H]3[C@]([C@@H]4[C@@]([C@@]5(C[C@@H](O)[C@]67CO[C@]5([C@@H]6CC(C)(C)CC7)C=C4)C)(C)CC3)(C)CC2)(C)CO)O[C@@H]([C@@H]1O)C)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O KYWSCMDFVARMPN-LCSVLAELSA-N 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 108010067390 Viral Proteins Proteins 0.000 description 1
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 1
- 238000011047 acute toxicity test Methods 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 238000003763 carbonization Methods 0.000 description 1
- 210000000845 cartilage Anatomy 0.000 description 1
- 108091092356 cellular DNA Proteins 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000003610 charcoal Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000036461 convulsion Effects 0.000 description 1
- 239000010779 crude oil Substances 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 238000012136 culture method Methods 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 230000000120 cytopathologic effect Effects 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 230000000531 effect on virus Effects 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- IDGUHHHQCWSQLU-UHFFFAOYSA-N ethanol;hydrate Chemical compound O.CCO IDGUHHHQCWSQLU-UHFFFAOYSA-N 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 238000002523 gelfiltration Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 208000002672 hepatitis B Diseases 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 208000026278 immune system disease Diseases 0.000 description 1
- 230000007813 immunodeficiency Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 229940010454 licorice Drugs 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000002250 progressing effect Effects 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 229930192014 saikosaponin Natural products 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 238000010898 silica gel chromatography Methods 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- DKVBOUDTNWVDEP-NJCHZNEYSA-N teicoplanin aglycone Chemical group N([C@H](C(N[C@@H](C1=CC(O)=CC(O)=C1C=1C(O)=CC=C2C=1)C(O)=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)OC=1C=C3C=C(C=1O)OC1=CC=C(C=C1Cl)C[C@H](C(=O)N1)NC([C@H](N)C=4C=C(O5)C(O)=CC=4)=O)C(=O)[C@@H]2NC(=O)[C@@H]3NC(=O)[C@@H]1C1=CC5=CC(O)=C1 DKVBOUDTNWVDEP-NJCHZNEYSA-N 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
Landscapes
- Saccharide Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
【発明の詳細な説明】
（産業上の利用分野）
本発明は、大豆中に存在する大豆サポニンを有効成分と
して含有するエイズ（後天性免疫不全症候群）予防およ
び治療用組成物に関する。DETAILED DESCRIPTION OF THE INVENTION (Field of Industrial Application) The present invention relates to a composition for preventing and treating AIDS (acquired immunodeficiency syndrome) containing soybean saponin present in soybeans as an active ingredient.
（従来の技術］
ＡＺＴ（アジドチミジン）には、エイズ患者の延命効果
があることが臨床試験により実証されている。(Prior Art) Clinical trials have demonstrated that AZT (azidothymidine) has a life-prolonging effect on AIDS patients.
また、甘草中のグリチルリチンにも抗エイズ作用がある
ことが報告され、その検討が続けられている。さらに最
近では、サイフ中のサイコサポニンについても抗エイズ
作用に関しての検討が行なわれている。It has also been reported that glycyrrhizin in licorice has anti-AIDS effects, and studies are continuing. Furthermore, recently, the anti-AIDS effect of saikosaponin in wallets has also been investigated.
（発明が解決しよりとする問題点）
ＡＺＴは、作用機序も解明され、患者の延命効果も認め
られてはいるが、一方、強い副作用をもつことが問題と
なっている。即ち、長期間ＡＺＴを連続投与すると、骨
髄に障害が現われ、重篤の貧血を招来したり、頭痛、け
いれんのような神経症状も発現せしめる。(Problems to be Solved by the Invention) Although the mechanism of action of AZT has been elucidated and the effect of prolonging the survival of patients has been recognized, on the other hand, the problem is that it has strong side effects. That is, continuous administration of AZT for a long period of time causes damage to the bone marrow, leading to severe anemia and neurological symptoms such as headaches and convulsions.
エイズの原因ウィルスであるＨ Ｉ Ｖ （ｈｕｍａｎ
ｉｍｍｕｎｏｄｅｆｉｃｉｅａｃｙ ｖｌ ｒｕｓ）
Ｋ感染した者は、体内からウィルスを完全に取シ除くこ
とが困難であることから、治療薬あるいは発症予防薬を
、生涯、投与され続けなければならない。そのため、治
療薬あるいは発症予防薬には、長期間の連用に酎えうる
ように、副作用の全くない薬剤あるいは副作用の少ない
薬剤が望まれるのである。HIV (human virus), the virus that causes AIDS
immunodeficiency vl rus)
Since it is difficult to completely eliminate the virus from the body of a person infected with K, they must continue to receive therapeutic drugs or preventive drugs for the rest of their lives. Therefore, it is desired that therapeutic or preventive drugs have no side effects or have few side effects so that they can be used continuously over a long period of time.
（問題点を解決するための手段）
本発明者らは、トリテルペノイド骨格をもつ配糖体化合
物に、抗炎症作用があること、および人血清よシ分離し
たＴｃｅｌｌ に対し、ある種のサポニンが特異的な作
用を示すことに着目した。(Means for Solving the Problems) The present inventors have discovered that glycoside compounds with a triterpenoid skeleton have anti-inflammatory effects, and that certain saponins have a specific effect on Tcell isolated from human serum. We focused on the fact that it exhibits a similar effect.
特に、大豆中のサポニンは、グリチルリチンと姻似の構
造であるが、トリテルペノイド骨格に２個ないし５個の
糖から成る糖鎖を持つ。これらの糖鎖とトリテルペノイ
ド骨格であるアグリコン部分との立体的構造が、ウィル
スに対し、何らかの作用を示すのではないかと想到し、
鋭意検討を続けた結果、大豆中のサポニンが抗エイズ作
用を示すことを発見し、本発明を完成するに至った。In particular, saponin in soybeans has a structure similar to that of glycyrrhizin, but has a sugar chain consisting of 2 to 5 sugars in a triterpenoid skeleton. We thought that the three-dimensional structure of these sugar chains and the aglycone moiety, which is a triterpenoid skeleton, might have some effect on viruses.
As a result of intensive research, the inventors discovered that saponin in soybeans exhibits anti-AIDS effects, leading to the completion of the present invention.
すなわち、本発明は、大豆中に含まれるサポニンを有機
成分として含有することを特徴とするエイズの予防およ
び治療用組成物を提供するものである。That is, the present invention provides a composition for preventing and treating AIDS, which is characterized by containing saponin contained in soybeans as an organic component.
本発明に係わるサポニンは、大豆種子中の種皮。The saponin according to the present invention is the seed coat in soybean seeds.
子葉、胚軸又は大豆植物体の葉柄、茎、根等に広（分布
するが、該サポニンは、トリテルペノイド骨格のアグリ
コンに結合する糖鎖の種類によって、Ａ型、Ｂ！ｕｎ大
別される。Ａｍサポニンは、アグリコン部のＯ−３位と
Ｃ−２２位とに糖鎖が結合しておシ、Ｂ型サポニンは、
アグリコン部のＯ−３位に糖鎖が結合している。本発明
の目的には、Ｂ型サポニンの方がよシ好ましい。Saponins are widely distributed in cotyledons, hypocotyls, petioles, stems, roots, etc. of soybean plants, and are broadly classified into type A and type B, depending on the type of sugar chain bonded to the aglycone of the triterpenoid skeleton. Am saponin has sugar chains attached to the O-3 and C-22 positions of the aglycon moiety, and B-type saponin has
A sugar chain is attached to the O-3 position of the aglycone part. For the purposes of the present invention, type B saponins are more preferred.
本発明に係わるサボニーンは、一般に次の方法によシ得
られる。■食用大豆を原料としてこれを抽出分離、精製
する方法、■大豆種子や大豆植物体中の成長活性点より
組織培養し、次いで抽出分離。Savonin according to the present invention is generally obtained by the following method. ■Method of extracting, separating, and purifying edible soybeans as raw materials; ■Tissue culture of active growth sites in soybean seeds and soybean plants, followed by extraction and separation.
精製する方法、■大豆を培地として担子菌菌糸体を培養
し１次いで抽出分離、精製する方法であシこれらの方法
によって得られた粗精製品を酸あるいはアルカリまたは
、酵素で分解することによって得ることができる。Purification method: ① Cultivating basidiomycete mycelium using soybean as a medium, followed by extraction, separation, and purification. The crude product obtained by these methods is decomposed with acid, alkali, or enzyme. be able to.
上記の方法によシ得られるサポニンは、原料大豆の種類
の培養方法（組織培養、菌糸体培養）、分解度合等によ
シサボニンの種類、菫に差があるが、下記の式ＡＩ、Ａ
２．Ｂｌ、Ｂ２で示される構造な持つ配糖体化合物であ
る。The saponin obtained by the above method varies depending on the type of raw soybean, the culture method (tissue culture, mycelial culture), the degree of decomposition, etc., but the saponin has the following formula AI, A
2. It is a glycoside compound with the structure shown by Bl and B2.
（式中、Ｒ５およびＲ６は前記と同じ意味である。(In the formula, R5 and R6 have the same meanings as above.
以下サポニンＡ、 と云う。） （式中、几６およびＲ・は前記と同じ意味である。Hereinafter referred to as saponin A. ) (In the formula, 几6 and R. have the same meanings as above.
以下サポニンＡ！ と云う。） 弐Ｂｌ （式中、恥および几７は前記と同じ意味である。Saponin A below! That's what it says. ) 2Bl (In the formula, shame and 几7 have the same meanings as above.
以下サポニンｎｕ と云う。）
弐Ｂ２
（式中、Ｒ１は前記と同じ意味である。以下サポニンＢ
３ と云う。）
大豆すＩニンには、前述の式ＡＩ、Ａ２．Ｂｌ。Hereinafter, it will be referred to as saponin nu. ) 2B2 (In the formula, R1 has the same meaning as above.Hereinafter referred to as saponin B
It says 3. ) Soybean oil contains formulas AI, A2. Bl.
Ｂ２に示される構造のものの他に武人ｌ、λ２゜Ｂｌ
、Ｂ２に示される構造を骨格として有すると考えられる
、構造未定の配糖体化合物も含まれており、これらの化
合物も本発明に係わるす７ｄニンに含まれる。In addition to the structure shown in B2, Takejin l, λ2゜Bl
, B2 and whose skeleton is thought to have an undetermined glycoside compound, and these compounds are also included in the 7d-nin according to the present invention.
前述の式ＡＩ 、Ａ２．Ｂｌ 、８２に示される構造を
持つサポニンの製造につき、その実施態様を述べれば次
の通）である。The aforementioned formula AI, A2. The embodiments for producing saponin having the structure shown in Bl, 82 are as follows.
まず■大豆、■大豆種子や大豆植物体中の成長活性点か
ら組織培養した培養物、または■大豆を培地として培養
した担子菌菌子体培養物を、あらかじめヘキサン、エー
テルなどの有機溶媒で脱脂した後、たとえばメタノール
での乾留抽出を行ない、サポニンを含む粗区分を得る。First, ■ soybean, ■ tissue culture cultured from growth active sites in soybean seeds or soybean plants, or ■ basidiomycete mycelium culture cultured using soybean as a medium, were degreased in advance with an organic solvent such as hexane or ether. Afterwards, a crude fraction containing saponin is obtained by performing a dry distillation extraction with, for example, methanol.
脱脂をしない場合は、たとえば６０９６〜８０％エタノ
ール水浴液でサポニンを含む粗精製油出品を得る。If no defatting is performed, a crude oil product containing saponin is obtained, for example, in a 6096-80% ethanol water bath.
いは、ｎ−ブタノール／酢酸／水系の溶剤を用いたシリ
カゲルクロマトグラフィー、高速液体クロマトグラフィ
ーなどにより、分離、ｆｉｎする。Alternatively, it is separated and finned by silica gel chromatography, high performance liquid chromatography, etc. using an n-butanol/acetic acid/water solvent.
これらのサポニンは、それぞれ単独で使用してもよいが
、二種またはそれ以上を混合して使用してもよい。These saponins may be used alone, or in combination of two or more.
本発明によるエイズ予防および治療用組成物は、有効成
分として式ＡＩ 、、Ａ２ 、Ｂｌ 、Ｂ２に示される
サポニンのいずれかまたはその混合物を、常用される医
薬組成物用担体と混合して、経口および非経口用の種々
の剤型、たとえば錠剤、丸剤。The composition for preventing and treating AIDS according to the present invention can be prepared by mixing any of the saponins represented by the formulas AI, , A2, BI, B2 or a mixture thereof as an active ingredient with a commonly used carrier for pharmaceutical compositions, and various dosage forms for parenteral use, such as tablets, pills.
カプセル剤、顆粒剤、液剤、注射剤、シロップ剤。Capsules, granules, liquids, injections, syrups.
軟骨剤などに製剤化することができる。必要に応じて、
安定剤、乳化剤、溶解補助剤等を混合してもよい。It can be formulated into cartilage agents, etc. as needed,
Stabilizers, emulsifiers, solubilizing agents, etc. may be mixed.
以下、実施例によシ具体的に説明する。The present invention will be specifically explained below using examples.
（実施例１）
エーテルで脱脂した１００．９の大豆胚軸成分を７０％
）タノール５１を用いて３時間、３回の乾留抽出を行い
、４．９ ！ｉの粗精製抽出物を得た。(Example 1) 70% of 100.9 soybean hypocotyl component defatted with ether
) Dry distillation extraction was performed 3 times for 3 hours using Tanol 51, and the result was 4.9! A crude extract of i was obtained.
この粗精製抽出物をメタノールＫＭかし、セファデンク
スＬｌｌ−２００カラムにのせ５０４〜ｌｏｏｍメタノ
ールで溶出させ、ＡＩおよびＡ、放物の人グループ混合
物０．９ｇ、ＢｔおよびＢ８成分のＢグループ混合物１
２Ｎを得た。This crude extract was filtered with methanol KM, loaded onto a Sephadenx Lll-200 column, and eluted with 504-room methanol.
I got 2N.
これらの各成分な逆相シリカゲルリクロゾルプ（Ｌｉｃ
ｈｒｏｓｏｒｂ）几ＰＬ−１８が充填されたローパーカ
ラムにて、Ａグループについては、アセトニトリル／ゾ
ロパノール／水／酢酸＝３２．３ ： ４．２ ： ６
３．４ ：０．１（Ｖ／Ｖ／Ｖ／Ｖ）で、Ｂグループに
ついては、メタノール／プロパツール／水／酢酸＝７０
．０ ： ６．０ ：２３、９ ： ０．１ （Ｖ／Ｖ
／Ｖ／Ｖ ） テ各々溶出すセ、ＵＶ（２０５ｎｍ）で
検出した。その結果、ＡＬが６５８．５９、Ａ、が１４
６．３！Ｗ／、Ｂ１が５９５．６′Ｊ９、Ｂ２が２６７
．７〜得られた。Reverse-phase silica gel liclosolp (Lic
For group A, acetonitrile/zolopanol/water/acetic acid = 32.3: 4.2: 6 using a Roper column packed with hrosorb) PL-18.
3.4:0.1 (V/V/V/V), and for group B, methanol/propertool/water/acetic acid = 70
．． 0: 6.0: 23, 9: 0.1 (V/V
/V/V) Each elution was detected using UV (205 nm). As a result, AL is 658.59, A is 14
6.3! W/, B1 is 595.6'J9, B2 is 267
．． 7 ~ obtained.
これらのＡｌ ｙＡ！を各々細胞傷害抑制試験およびウ
ィルス抗原発現抑制試験に使用した。These Al yA! were used in the cytotoxicity suppression test and viral antigen expression suppression test, respectively.
（実施例２）
脱皮および脱胚軸処理した大豆を培地として担子飽の一
種であるマンネンタケ菌糸体を用いた培養生成物１００
ｇを、７０係エタノール５１を用いて３時間処理する。(Example 2) Cultivation product 100 using Soybean mycelium, which is a type of Basidios, using dehulled and hypocotyl-treated soybeans as a medium
g is treated with 70% ethanol 51 for 3 hours.
これを３回くり返し乾留抽出を行なう。粗抽出ｎ！Ｒ物
が７００ｍ９得られた。This process is repeated three times to perform carbonization extraction. Rough extraction n! 700 m9 of R product was obtained.
この粗精製抽出物を実施例１と同じ条件でゲル濾過分取
しＢ１およびＢ、混合物のＢグループが１７１４ｑ得た
。これらの各成分を実施例１と同様の方法で分離精製を
行いＢ１５Ｊをそれぞれ、８５．１〜，３８．２ダ得た
。This crudely purified extract was fractionated by gel filtration under the same conditions as in Example 1 to obtain 1714q of B1 and B, and group B of the mixture. These components were separated and purified in the same manner as in Example 1 to obtain B15J of 85.1 to 38.2 Da, respectively.
これらの方法で得られたＢ１．Ｂ！酸成分実施例１で得
られたＢｌｐＪとそれぞれ混合し試料とした。混合した
Ｂ１およびＢ！は、それぞれ細胞傷害抑制試験およびウ
ィルス抗原発現抑制試験に使用した。B1. obtained by these methods. B! The acid component was mixed with BlpJ obtained in Example 1 to prepare a sample. Mixed B1 and B! were used in the cytotoxicity suppression test and viral antigen expression suppression test, respectively.
（発明の効果）
本発明による組成物の適用範囲は、エイズ予防および治
療用であるが、エイズ以外の免疫不全症。(Effects of the Invention) The composition according to the present invention is applicable to prevention and treatment of AIDS, but also to immunodeficiency diseases other than AIDS.
感染症（Ｂ型肝炎など）、悪性腫瘍などを含めた感染症
や免疫疾患に対して有用であると推定される。It is estimated that it is useful for infectious diseases (such as hepatitis B), infectious diseases including malignant tumors, and immune diseases.
本発明に係わるサポニンのうち、大豆から抽出分離した
各種サポニン混合物の、マウスにおける急性毒性試験結
果を第１表に示す。Table 1 shows the results of acute toxicity tests on mice of various saponin mixtures extracted and separated from soybeans among the saponins according to the present invention.
次に本発明に係わるサポニンの、ｉｎ ｖｉｔｒｏ試験
について述べる。Next, an in vitro test of the saponin according to the present invention will be described.
〈試験１〉 細胞傷害抑制試験
成人Ｔ細胞白血病の原因ウィルスであるＨＴＬＶ−１陽
性細胞株のＭＴ−４細胞に、エイズの原因ウィルスであ
るＨＩＭ ？感染させると、細胞質内にＨＩｖの抗原蛋
白質が出現し、細胞のＤＮＡ合成が抑制され、細胞変性
効果（ＯＰＥ）によシ、感染細胞が死滅していく現象を
利用して、抗ＨＩｖ効果を判定する方法によシ試験した
。<Test 1> Cytotoxicity Suppression Test HIM, the virus that causes AIDS, was applied to MT-4 cells, a positive cell line of HTLV-1, which is the virus that causes adult T-cell leukemia. When infected, the antigen protein of HIV appears in the cytoplasm, inhibits cellular DNA synthesis, causes cytopathic effect (OPE), and kills the infected cells. It was tested according to the method of determination.
すなわち、ＭＴ−４細胞はＨＩＶ感染によシ、２日ない
し３日経過するとウィルスによって細胞が破壊されはじ
め、６日ないし７日後には、はとんどの細胞が死滅する
。あらかじめ、種々の濃度に希釈した被験物質と、ＨＩ
ｖに感染したＭＴ−４細胞とを、９６穴マイクロプレー
トで混在させて培養すると、被験物質が抗エイズ効果を
有する場合には、細胞は細胞変性による破壊から免れて
増殖を続ける。このことは、肉眼で観察することも可能
であシ、また、トリパンブルー染色法により生細胞゛数
を算定することにより、定量的計測を行なうこともでき
る。なお、１１工ｖに感染していないＭＴ −４細胞に
、被験物質のみを暴露させて培養したもの全コントロー
ルとすることによシ、同時に、被験物質の細胞毒性を調
べることもできる。具体的には、以下に示す方法で評価
した。That is, MT-4 cells are susceptible to HIV infection, and after 2 to 3 days, the cells begin to be destroyed by the virus, and after 6 to 7 days, most of the cells die. Test substances diluted in advance to various concentrations and HI
If the test substance has an anti-AIDS effect, the cells will continue to proliferate without being destroyed by cell degeneration. This can be observed with the naked eye, and can also be quantitatively measured by counting the number of living cells using trypan blue staining. It is also possible to simultaneously examine the cytotoxicity of the test substance by culturing MT-4 cells that have not been infected with the test substance and exposing them to only the test substance as a control. Specifically, evaluation was performed using the method shown below.
３ Ｘ １０”／ゴに調整したＭＴ−４細胞’ｌｉ−Ｈ
ＩＶの１株であるＨＴＬＶ −ｍＢにｍｏｉ ： ０．
００２で感染させ、種々の濃度に稀釈した試験薬を加え
て、３７℃、 Ｃｏ２インキュベーターにて培養した。MT-4 cells adjusted to 3 x 10"/g'li-H
moi for HTLV-mB, a strain of IV: 0.
002, test drugs diluted to various concentrations were added, and the cells were cultured at 37°C in a Co2 incubator.
細胞の調整および薬剤の稀釈は１０％ＦＯ８添加ＲＰＭ
ｉ １６４０培養液を用いた。培養開始后３日目にトリ
パンブルー染色法にて生細胞数を測定し、ＩＩＩＶ感染
による細胞傷害全評価判定した。Cell preparation and drug dilution at RPM with 10% FO8
i1640 culture solution was used. On the third day after the start of culture, the number of living cells was measured by trypan blue staining, and the total cytotoxicity due to IIIV infection was evaluated.
薬物の抗ＨＩＶ作用が有効なものでは、細胞の生存率が
保たれ、生細胞数は増加していた。In cases where the drug had an effective anti-HIV effect, cell survival rate was maintained and the number of living cells increased.
この時、薬剤の宿生細胞に対する毒性をみるため、Ｈ’
ｒＬＶ−ｍ、に感染させていないＭＴ−４細胞を使用し
て同様に薬剤を加えて培養し、細胞数ｋ ｆｉｌ定した
。３日目の測定数、再び細胞数が３Ｘｉ０５〜５ Ｘ
１０Ｓ／ゴになるように、薬剤を各々試験開始日と同じ
濃度になるように新しい培養液を加えて、さらに培養を
続け、６日目に同様に生細胞数を測定した。At this time, in order to examine the toxicity of the drug to host cells, H'
MT-4 cells not infected with rLV-m were similarly cultured with the addition of the drug, and the number of cells kfil was determined. Measurement number on the 3rd day, again the cell number is 3Xi05~5X
A new culture solution was added so that the concentration of each drug was the same as on the test start day, and the culture was continued. On the 6th day, the number of viable cells was measured in the same manner.
試験結果は、経日変化がわかるように、各種サポニン毎
に、感染３日後、６日後の結果金、それぞれ第１図〜第
４図に示す。図から明らかなように、感染３日後では、
いずれのサポニンにおいても抗エイズ効果が認められる
。しかし、感染６日後の結果においては、サポニンＢ１
に最も大きい抗エイズ効果が１りシ、他のサポニンの効
果は、サポニンＢ１に比較すると弱くなっている。また
感染６日後においては、高濃度の投与により、細胞毒性
が認められる。The test results are shown in Figures 1 to 4 for each type of saponin, 3 days and 6 days after infection, respectively, so that the changes over time can be seen. As is clear from the figure, 3 days after infection,
Anti-AIDS effects are observed in all saponins. However, in the results 6 days after infection, saponin B1
Saponin B1 has the greatest anti-AIDS effect, while the effects of other saponins are weaker than saponin B1. Furthermore, 6 days after infection, cytotoxicity is observed when administered at a high concentration.
単独使用の場合は、Ｂｌタイプのサポニンに抗エイズ効
果がみられ、ＡＺＴ（アジドチミジン）と同程度の効果
が認められた。When used alone, Bl type saponin had an anti-AIDS effect, and was found to have an effect comparable to that of AZT (azidothymidine).
〈試験２〉 ウィルス抗原発現抑制試験成人Ｔ細胞白血
病の原因ウィルスである１（Ｔ Ｌ Ｖ−１陽性細胞株
のＭＴ−４細胞は、ｌ−Ｉ Ｉ Ｖに感染すると、ＨＩ
Ｖ抗原蛋白質を発現し、感染５日目ないし７日目には、
はぼ１００％の細胞が、ウィルス抗原陽性となる。これ
は抗ＨＩＶ抗体陽性血清を１次抗体とした間接螢光抗体
法を用いることで判定できろ。ＨＩＭに感染したＭＴ−
４細胞に被験物質を加えて培養し、ウィルス抗原陽性細
胞数に計測することにより、抗エイズ効果を評価するこ
とができる。<Test 2> Viral antigen expression suppression test When MT-4 cells, a positive cell line of TLV-1 (TLV-1), which is the causative virus of adult T-cell leukemia, are infected with l-IIV,
V antigen protein is expressed, and on the 5th to 7th day of infection,
Almost 100% of cells become positive for virus antigen. This can be determined by using an indirect fluorescent antibody method using anti-HIV antibody positive serum as the primary antibody. MT infected with HIM-
The anti-AIDS effect can be evaluated by adding the test substance to 4 cells, culturing them, and counting the number of virus antigen-positive cells.
具体的には、以下に示す方法で評価した。Specifically, evaluation was performed using the method shown below.
ＨＩＶ ｆ ｍｏｉ ： ０．００２で感染させたＭＴ
−４細胞に種々の濃度の薬剤金加えて培養し、感染後
３日目と６日目に、その培養細胞の一部を採取し、遠心
後細胞をスライド・グラスに付着させ、風乾・冷アルコ
ール固定後、間接螢光抗体法を用いて判定した。ＨＩＭ
に感染し、ウィルス蛋白質を発現している細胞は、螢光
顕微鏡で観察することで検出される。５００個以上の細
胞を観察し、そのうちウィルス抗原陽性細胞の百分率を
算出した。薬剤の抗ＨＩＶ作用が有効な場合、ウィルス
抗原陽性細胞の出現は、薬剤を加えていないコントロー
ルに較べて低値を示した。MT infected with HIV f moi: 0.002
-4 cells were cultured with various concentrations of drug gold added, and on the 3rd and 6th day after infection, a part of the cultured cells was collected, and after centrifugation, the cells were attached to slides/glasses, air-dried, and cooled. After fixation with alcohol, determination was made using indirect fluorescent antibody method. HIM
Cells infected with the virus and expressing viral proteins can be detected by observation with a fluorescence microscope. More than 500 cells were observed, and the percentage of virus antigen-positive cells among them was calculated. When the anti-HIV effect of the drug was effective, the appearance of virus antigen-positive cells was lower than in the control to which no drug was added.
試験結果は、経口変化がわかるように、各種サポニン毎
に、感染３日後、６日後の結果を、それぞれ第５図〜第
８図に示す。なお、この試験は細胞傷害抑制試験にそれ
ぞれ対応して評価できるように実施した。The test results are shown in Figures 5 to 8 for each type of saponin, 3 days and 6 days after infection, respectively, so that oral changes can be seen. In addition, this test was carried out so that it could be evaluated in accordance with the cytotoxicity inhibition test.
すなわち、第１図および第５図における感染３日後の結
果では、細胞障害抑制試験とウィルス抗原発現抑制試験
とＫ、各濃度毎に対応して評価できる。す７ｊ？ニン人
ｌの濃度が０．２５■／ｄの時、細胞障害抑制試験では
、ＨＩｖ感染細胞は、非感染細胞に比べ、ＨＩＶ感染に
よる細胞破壊が認められた。That is, the results 3 days after infection shown in FIGS. 1 and 5 can be evaluated in correspondence to each concentration of the cytotoxicity suppression test, viral antigen expression suppression test, and K. Su7j? When the concentration of Ninjin 1 was 0.25 μ/d, in the cytotoxicity inhibition test, cell destruction due to HIV infection was observed in HIV-infected cells compared to non-infected cells.
それに対応して、第５図におけるウィルス抗原発現の様
子をみると０．２５１１１ｉ／ａｕの濃度では、全細胞
の約７５％の細胞に抗原が発現しており、ＨＩＭ感染が
進行していることが示されている。Correspondingly, looking at the state of viral antigen expression in Figure 5, at a concentration of 0.25111i/au, the antigen is expressed in approximately 75% of all cells, indicating that HIM infection is progressing. It is shown.
試験１、試験２の結果をまとめると、ＩＩＩｖ感染３日
後ではどのタイプのサポニンも、ある濃度領域では、ウ
ィルス抑制効果が認められる。また、ＨＩｖ感染感染６
マ後、サポニンＢｌにウィルス抑制効果が最も強く、こ
の効果は、ＡＺＴと同程度の抗エイズ効果であることが
わかる。To summarize the results of Tests 1 and 2, three days after infection with IIIv, any type of saponin has a virus-inhibiting effect within a certain concentration range. In addition, HIV infection 6
It can be seen that saponin Bl has the strongest virus-inhibiting effect, and this effect is comparable to that of AZT.
第１図〜第４図は、感染３日後および６日後の細胞侵害
抑制をサポニン投与濃度と生細胞数との関係で表わした
グラフであり、第１図はサポニンに１ｓ第２図はサポニ
ンＡ２、第３図はサポニンＢ１、第４図はサポニンＢ、
全投与した場合を表わしている。
第５図〜第８図は、感染３日後および６日後のウィルス
抗原発現抑制をサポニン投与濃度とウィルス抗原陽性細
胞の百分率との関係で表わしたグラフであシ、第５図は
サポニンＡｌｓ第６図はサポニンｈｘ、第７図はサポニ
ン８１％第８図はサポニンＩｈｆｆ１投与した場合全表
わしている。
特許出願人 旭化成工業株式会社
ＨＩＶ感染感染３更
イ更Ｆ
Ｐｏｓｉｔｉｖｅ
Ｃ・１１＄
Ｃ％）
０ α１２５０．２５ Ｑ５ １ ２）災与ＪＴｖ
ｔｍｑ／ｍｒ）
５図
Ｃ・１１廖
（％１
０ ０４２５０．２５ ０．５ １ ２投＋濃＆ Ｃ
ｍｇ／ｍ＋）
第 ８
１．Ｆ。
Ｐｏ５ｌｔｌｖ・
（ｅｌｆｓ
設＋濃准（四／ｍ１）
ＨＩＶ應、采６日僕
１、Ｆ、
〜＄けｌｖ＠
ｅｌｌｓ
設Ｓ濃炭（ｍｇ／ｍｌ）Figures 1 to 4 are graphs showing the inhibition of cell noxiousness 3 and 6 days after infection in terms of the relationship between the saponin administration concentration and the number of viable cells. , Figure 3 shows saponin B1, Figure 4 shows saponin B,
The figure represents the case where all doses were administered. Figures 5 to 8 are graphs showing the suppression of viral antigen expression 3 and 6 days after infection in relation to the saponin administration concentration and the percentage of virus antigen-positive cells. The figure shows saponin hx, FIG. 7 shows saponin 81%, and FIG. 8 shows saponin Ihff1. Patent applicant Asahi Kasei Kogyo Co., Ltd. HIV infection 3rd renewal F Positive C・11$ C%) 0 α1250.25 Q5 1 2) Disaster JTv
tmq/mr) 5 Figure C・11 Liao (%1 0 04250.25 0.5 1 2 throws + dark & C
mg/m+) Part 8 1. F. Po5ltlv・ (elfs set + thick associate (4/m1) HIV 應、采6日 1、F、〜$ketlv@ells set S thick charcoal (mg/ml)
Claims (2)
とを特徴とするエイズ予防および治療用組成物(1) A composition for preventing and treating AIDS characterized by containing soybean-derived saponin as an active ingredient
範囲第１項記載のエイズ予防および治療用組成物▲数式
、化学式、表等があります▼（ I ） （式中、Ｒ＿１はＨ、ＣＯＯＨ又はＯＨ＿２ＯＨ、Ｒ＿
２はＨ、▲数式、化学式、表等があります▼、▲数式、
化学式、表等があります▼または▲数式、化学式、表等
があります▼ Ｒ＿３はＲ＿４がＨの場合はＨ、Ｒ＿４がＨ以外の場合
はＯＨ、Ｒ＿４はＨ又は▲数式、化学式、表等がありま
す▼ Ｒ＿５はＨ、ＯＨ＿２ＯＨまたはＣＯＯＨ＿３、Ｒ＿６
はＨ、ＣＯＣＨ＿３又は ▲数式、化学式、表等があります▼ Ｒ＿７は、ＣＯＯＨ、ＣＨ＿２ＯＨ又はＣＨ＿３を表わ
す。但しｎは１〜１０００である。）(2) The composition for preventing and treating AIDS according to claim 1, in which the saponin is represented by the general formula (I) ▲ Numerical formulas, chemical formulas, tables, etc. ▼ (I) (wherein R_1 is H, COOH or OH_2OH, R_
2 is H, ▲ There are mathematical formulas, chemical formulas, tables, etc. ▼, ▲ Mathematical formulas,
There are chemical formulas, tables, etc. ▼ or ▲ There are mathematical formulas, chemical formulas, tables, etc. ▼ R_3 is H if R_4 is H, OH if R_4 is other than H, R_4 is H or ▲ There are mathematical formulas, chemical formulas, tables, etc. ▼ R_5 is H, OH_2OH or COOH_3, R_6
is H, COCH_3 or ▲ There are mathematical formulas, chemical formulas, tables, etc. ▼ R_7 represents COOH, CH_2OH or CH_3. However, n is 1 to 1000. )
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP25726887A JPH01100126A (en) | 1987-10-14 | 1987-10-14 | Aids-preventing and treating composition |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP25726887A JPH01100126A (en) | 1987-10-14 | 1987-10-14 | Aids-preventing and treating composition |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JPH01100126A true JPH01100126A (en) | 1989-04-18 |
Family
ID=17304020
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP25726887A Pending JPH01100126A (en) | 1987-10-14 | 1987-10-14 | Aids-preventing and treating composition |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPH01100126A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7285279B2 (en) | 1999-07-09 | 2007-10-23 | Sun Farm Corporation | Method of treating malignancies and viral infections and improving immune function with a dietary supplement |
-
1987
- 1987-10-14 JP JP25726887A patent/JPH01100126A/en active Pending
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7285279B2 (en) | 1999-07-09 | 2007-10-23 | Sun Farm Corporation | Method of treating malignancies and viral infections and improving immune function with a dietary supplement |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US7045159B1 (en) | Antiviral substances from plant cuticular and epiciticular material | |
| KR100651650B1 (en) | Anti-cancer composition comprising sesquiterpene compounds isolated from ferulae resina | |
| Esimone et al. | In vitro evaluation of the antiviral activity of extracts from the lichen Parmelia perlata (L.) Ach. against three RNA viruses | |
| DE69403063T2 (en) | AGAINST VIRUS-ACTIVE NAPHTOCHINONE COMPOUNDS, COMPOSITIONS AND THEIR USE | |
| US20050287230A1 (en) | Method of producing ginsenoside 20 (R)-Rh2 and composition of matter thereof | |
| WO1998056755A1 (en) | Physiologically active substances tkr2449, process for producing the same, and microorganism | |
| CN114948936B (en) | Natural antiviral atomized liquid and preparation method and application thereof | |
| CN113521060B (en) | Application of NEEDOLIDE in resisting novel coronavirus | |
| JPH01100126A (en) | Aids-preventing and treating composition | |
| CN105712982B (en) | Dihydro- β -agarofuran type sesquiterpenoids, preparation method and application thereof | |
| JPH11302191A (en) | Immunoactivator and antitumor agent containing extract from lyophyllum decastes (fr.) sing. as active ingredient | |
| Sun et al. | Suppressive effects of metabolites from Alternaria brassicaea on the hepatitis B surface antigen | |
| JP4979053B2 (en) | Anticancer agent containing gentian extract, health supplement and medicinal cosmetic, and method for producing gentian extract | |
| US5091181A (en) | Asphodelus composition for increasing white blood cell count | |
| EP0289203B1 (en) | Antitumor and antiviral compounds of marine origin | |
| KR100458003B1 (en) | New anticancer compound and its purification from Asparagus oligoclonos | |
| JPH01500516A (en) | Guaiazulene derivatives and their usage | |
| JP3490757B2 (en) | Neutrophil activator | |
| JPH08231539A (en) | New lignan glycoside | |
| JP2006519752A (en) | Pharmaceutical composition useful for treating chronic myeloid leukemia | |
| JPH07188245A (en) | New compound contained in 'kukanzo' | |
| AU3756995A (en) | Use of anthocyanidin and derivatives for treatment of retroviral infections | |
| WO1996011692A9 (en) | Use of anthocyanidin and derivatives for treatment of retroviral infections | |
| JPH0259525A (en) | Vermifuge for treatment composed of acetogenin | |
| KR100242240B1 (en) | Process for the preparation of sesquiterpene lacton compounds for angiogenesis inhibitor from carpesium adrotanoides l and composition containing same |